Guardant Health Inc (NASDAQ:GH) and Exact Sciences Corp (NASDAQ:EXAS) shares are moving in different directions in Thursday’s after-hours session. Here’s a look at what’s going on.
What To Know: Guardant Health shares are plunging after the company announced results from its ECLIPSE study evaluating the performance of its blood test for detecting colorectal cancer.
The test demonstrated 83% sensitivity in detecting individuals with colorectal cancer. Specificity was 90% in both individuals without advanced neoplasia and in those who had a negative colonoscopy result.
Exact Sciences owns Cologuard, a stool-based cancer test that would directly compete with Guardant Health’s blood test. Cologuard is FDA approved and identifies 92% of colorectal cancers, according to data from the company.
From Last Month: After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
GH, EXAS Price Action: Guardant Health shares are down 40.6% in after hours at $24.50, while Exact Sciences shares are up 25.8% at $56.10, according to Benzinga Pro.
Photo: fernando zhiminaicela from Pixabay.
